In recent years, scientific inquiry has taken a keen interest in the potential neuroprotective properties of breastmilk beyond its established nutritional and immunological benefits. A burgeoning area of research now explores whether breastmilk, particularly from mothers of preterm infants, could hold therapeutic promise for neonatal neuroprotection. This hypothesis pivots on the discovery of viable stem and stromal cells — including mesenchymal stem cells (MSCs) — present in fresh breastmilk, which may contribute to brain development and repair mechanisms in vulnerable neonates.
One critical aspect underlined by recent studies is the necessity for fresh, regularly supplied breastmilk to maintain the viability of these therapeutic cells. It has been demonstrated that refrigeration can diminish the live MSC count, while freezing leads to an almost complete eradication of these vital components. This poses substantial challenges in harnessing breastmilk for clinical neuroprotective protocols since preservation techniques common in milk banking reduce the active cellular content that may be fundamental for therapeutic efficacy.
Central to current discussions is the variability of stem and stromal cell concentrations within breastmilk, which fluctuates significantly depending on the time postpartum and other maternal factors. This lack of consistency makes precise dosing of stem cells in breastmilk therapy complex. Researchers like Tarjanyi and colleagues have postulated an effective therapeutic range of approximately 0.5 to 1.5 million stem cells per kilogram of neonatal body weight for treating neurological disorders. Their calculations suggest that some intranasal breastmilk administration protocols might deliver around 1.4 million stem cells per kilogram over a 28-day period — though this figure is largely extrapolated rather than empirically measured.
The basis for such extrapolations draws in part on findings from Hoban et al., who analyzed 21 breastmilk samples spanning days 6 to 77 postpartum from mothers of preterm infants. Their data indicated median total cell counts of about 0.23 million cells per milliliter, with varying proportions classified as putative pluripotent stem cells — ranging from 0 to 44 percent — and approximately 5 percent putative mesenchymal stem cells. This heterogeneity, while illuminating the complex cellular milieu within breastmilk, complicates attempts to standardize dosing for clinical application.
Further meta-analyses, including a noteworthy review by Syaidah and colleagues, add some breadth to these estimates, suggesting that protocols like the F-NEO-BRIGHT regimen could theoretically deliver from 4 to 50 million human breastmilk stem cells over 28 days. Translating these numbers into clinically actionable dosages remains speculative, particularly given the unknowns surrounding the minimum effective volume and duration of breastmilk exposure necessary to achieve meaningful neuroprotection or neurorepair in neonates.
Beyond cellular counts, other pragmatic considerations loom large. For instance, the highest conceivable yield of stem cells from colostrum administration — about 1.6 milliliters per day — might amount to roughly 3 million stem cells per kilogram over a 48-hour period. However, given that neither the volume requirements nor the temporal dynamics of treatment have been conclusively established, any assumptions regarding therapeutic thresholds remain tentative. This represents a key obstacle in translating laboratory findings into bedside interventions.
At the forefront of these explorations is the innovative yet controversial approach of intranasal delivery of fresh breastmilk. This route is proposed to bypass systemic metabolism and facilitate direct access to the central nervous system, potentially enhancing the therapeutic impact of breastmilk’s stem cell components. While conceptually compelling, this strategy raises significant regulatory and safety considerations. The use of human cell and tissue products in clinical therapy is stringently governed by medicines regulatory bodies worldwide, especially when stem cells are involved.
In many jurisdictions, mother’s own milk feeding is rightly unregulated due to its long-standing role in infant nutrition and care. Likewise, the ad hoc use of breastmilk as a home remedy — such as for relief of nasal congestion — does not typically trigger regulatory oversight. However, the question of whether intranasal administration of a mother’s own breastmilk, specifically for neuroprotective purposes, should come under stricter regulatory purview is a subject of considerable debate. The stance adopted can vary depending on local legislation and the interpretations of relevant authorities.
Besides regulatory frameworks, considerable scientific rigor is required to determine efficacy and safety profiles of breastmilk-derived neuroprotective therapies. Randomized clinical trials with well-defined endpoints, careful stratification for prematurity and neurological risk, and precise quantitative assessments of cellular and molecular constituents are urgently needed. Until such evidence is available, clinical adoption remains premature.
Moreover, the biological mechanisms underpinning the neuroprotective potential of breastmilk-derived stem cells are an area of active investigation. These cells may support neurogenesis, modulate immune responses within the brain, or enhance repair pathways following hypoxic-ischemic injury. Understanding these pathways in molecular detail could guide optimization of dosing strategies and identify biomarkers predictive of therapeutic response.
The interplay between breastmilk’s stem cell populations and neonatal developmental trajectories also merits deeper exploration. The dynamic changes in breastmilk composition across different stages of lactation may reflect evolutionary adaptations geared towards supporting the unique needs of preterm versus term infants. Disentangling these variables offers an opportunity to tailor interventions more precisely to individual neonatal conditions.
Technical advances in single-cell sequencing, flow cytometry, and imaging are poised to accelerate our understanding of breastmilk’s cellular heterogeneity, function, and therapeutic capacity. Such technologies could enable real-time monitoring of stem cell viability and potency in fresh and stored breastmilk, providing critical parameters for clinical implementation.
In conclusion, the concept that “breast is best” may extend beyond nutrition and immunity to encompass promising avenues in neonatal neuroprotection. However, much remains to be elucidated regarding the optimal sourcing, handling, dosing, delivery, and regulatory governance of breastmilk-based stem cell therapies. Interdisciplinary collaboration among neonatologists, neuroscientists, cell biologists, and regulatory experts will be essential in translating this exciting science into safe and effective clinical practice. The prospect of harnessing a mother’s own milk to mend and protect the developing infant brain stands as a modern pinnacle of personalized and natural medicine.
As research advances, the neonatal community awaits more definitive answers about how fresh breastmilk’s unique cellular components can be leveraged for neuroprotection. This represents a profound opportunity to improve outcomes for the most vulnerable newborns, underlining the enduring biological wisdom encapsulated in the humble act of breastfeeding.
Subject of Research: The neuroprotective potential of fresh human breastmilk stem/stromal cells in neonatal care, specifically their viability, dosage, and therapeutic implications for neurorepair in preterm and at-risk infants.
Article Title: “Breast is Best”: does this also apply to neonatal neuroprotection?
Article References:
Martinello, K.A., Pang, R., Lowdell, M.W. et al. “Breast is Best”: does this also apply to neonatal neuroprotection?. Pediatr Res (2026). https://doi.org/10.1038/s41390-026-05154-6
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41390-026-05154-6
Tags: breastmilk and brain developmentbreastmilk for preterm infantsbreastmilk neuroprotection researchbreastmilk stem cell variabilitychallenges in breastmilk therapyeffects of refrigeration on breastmilkmesenchymal stem cells in breastmilkneonatal brain protectionneuroprotective properties of breastmilkpreservation of breastmilk cellsstem cells in breastmilktherapeutic use of breastmilk
